Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Lower Mortality Rates Shown with LDCT Screening

By Medimaging International staff writers
Posted on 24 Oct 2017
Print article
Image: The image shows a Low-Dose CT (LDCT) lung cancer scan (Photo courtesy of Siemens Healthineers).
Image: The image shows a Low-Dose CT (LDCT) lung cancer scan (Photo courtesy of Siemens Healthineers).
A new study has shown that by combining Low-Dose CT (LDCT) lung cancer screening program with robust programs that help people stop smoking can reduce mortality rates, and be cost-effective.

The researchers used OncoSim-LC, a microsimulation model to compare screening scenarios with smoking-cessation, to those without a cessation program, and projected this over 20 years.

The findings were presented by researchers from the McMaster University (Hamilton, ON, Canada) at the 18th World Conference on Lung Cancer (WCLC) organized by the International Association for the Study of Lung Cancer (IASLC), in Yokohama, Japan. The results of OncoSim-LC microsimulation model study showed that by adding a smoking-cessation program to an organized LDCT screening program was relatively cost effective, and resulted in significantly fewer deaths.

Additional research is required to determine the structure of such joint programs, to determine the detailed economic requirements, and to ensure that participants continue to adhere to both LDCT and smoking cessation programs.

Dr. William Evans, from the McMaster University, said, "To achieve the maximal benefits of a LDCT screening program, it is essential to incorporate a robust smoking cessation intervention. In my long career as an oncologist, I have not been able to save any patients from advanced non-small cell lung cancer. I believe that an organized lung screening program can be used to provide teachable moments for heavy smokers and, ultimately, save lives."

Related Links:
McMaster University


Print article
Radcal

Channels

Copyright © 2000-2017 Globetech Media. All rights reserved.